Filtered By:
Condition: Heart Attack
Drug: Methotrexate

This page shows you your search results in order of date.

Order by Relevance | Date

Total 25 results found since Jan 2013.

Psoriasis a Cause of Cardiovascular Diseases: A Review Article
Cureus. 2022 Aug 8;14(8):e27767. doi: 10.7759/cureus.27767. eCollection 2022 Aug.ABSTRACTPsoriasis is a severe, chronic inflammatory disease characterized by erythematous plaques across the extensor surfaces of the skin. Psoriasis has been linked to a higher threat of vascular events like myocardial infarction and stroke. Other associated cardiovascular disorders in the case of psoriasis include building up atherosclerosis, non-ischemic dilated cardiomyopathy, and psoriatic arthritis. Individuals can use International Classification of Diseases (ICD-9) codes to identify cardiovascular disease/comorbidities and related risk...
Source: Atherosclerosis - September 15, 2022 Category: Cardiology Authors: Aditi Gupta Bhushan Madke Source Type: research

Examining anti-inflammatory therapies in the prevention of cardiovascular events: protocol for a systematic review and network meta-analysis of randomised controlled trials
Introduction Inflammation is emerging as an important risk factor for atherosclerotic cardiovascular disease and has been a recent target for many novel therapeutic agents. However, comparative evidence regarding efficacy of these anti-inflammatory treatment options is currently lacking. Methods and analysis This systematic review will include randomised controlled trials evaluating the effect of anti-inflammatory agents on cardiovascular outcomes in patients with known cardiovascular disease. Studies will be retrieved from Medline, Embase, the Cochrane Central Register of Controlled Trials, as well as clinical trial regi...
Source: BMJ Open - June 27, 2022 Category: General Medicine Authors: Boczar, K. E., Shin, S., Bezzina, K. A., Geejo, A., Pearson, A. L., Shahab, S., Fehlmann, C. A., Visintini, S., Beanlands, R., Wells, G. A. Tags: Open access, Cardiovascular medicine Source Type: research

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Patients with rheumatoid arthritis have impaired long-term outcomes after myocardial infarction: a nationwide case-control registry study
ConclusionRA is independently associated with poorer prognosis after MI. RA duration and corticosteroid usage and dosage were independent predictors of mortality after MI in RA. Special attention is needed for improvement of outcomes after MI in this vulnerable population.
Source: Rheumatology - March 1, 2021 Category: Rheumatology Source Type: research

Benefits of Methotrexate Use on Cardiovascular Disease Risk among Rheumatoid Arthritis Patients Initiating Biologic Disease-Modifying Antirheumatic Drugs.
CONCLUSION: Among RA patients receiving biologics, concomitant methotrexate use was associated with a 24% lower risk for CVD events. PMID: 33060309 [PubMed - as supplied by publisher]
Source: J Rheumatol - October 15, 2020 Category: Rheumatology Authors: Xie F, Chen L, Yun H, Levitan EB, Curtis JR Tags: J Rheumatol Source Type: research

Targeting Inflammation to Reduce Residual Cardiovascular Risk
AbstractPurpose of ReviewPatients with established cardiovascular disease are at high risk for recurrent myocardial infarction, stroke, and cardiovascular death. The termresidual risk refers to this risk that persists, even after optimal treatment. Considerable progress has been made to understand the biological basis of residual risk and to devise therapies that can safely and effectively reduce risk. The presence of ongoing subclinical vascular inflammation is known to be a marker of elevated residual risk, and reductions in measures of vascular inflammation predict improved outcome in these patients.Recent FindingsRecen...
Source: Current Atherosclerosis Reports - September 2, 2020 Category: Cardiology Source Type: research

The risk of cardiovascular events associated with disease-modifying antirheumatic drugs in rheumatoid arthritis.
CONCLUSION: Abatacept and TNFi were associated with decreased risk of CVD compared to csDMARDs. Minimizing glucocorticoid use and optimizing MTX dose may improve CV outcomes in patients with RA. PMID: 32801134 [PubMed - as supplied by publisher]
Source: Journal of Rheumatology - August 18, 2020 Category: Rheumatology Tags: J Rheumatol Source Type: research

Targeting Inflammation and Immune System in Acute Myocardial Infarction.
Authors: Alwi I Abstract Over more than two decades, the concept of atherosclerosis has developed and lead to inflammatory hypothesis. Inflammation plays an important role on pathogenesis of atherothrombosis and coronary heart disease (CHD), including acute coronary syndrome (ACS). Although the management of ACS has been demonstrated to be beneficial for secondary prevention of coronary heart disease (such as using statin and aspirin) and also seemed to have positive effect on inflammation, the identification of effective management, specifically targeting inflammation, has been not been comprehensively understood....
Source: Acta medica Indonesiana - February 13, 2020 Category: Internal Medicine Tags: Acta Med Indones Source Type: research

Low-Dose Methotrexate Does Not Reduce Risk of Cardiovascular Events
Inexpensive generic drug neither inhibited critical inflammatory pathways nor reduced rates of heart attack, stroke and cardiovascular death
Source: BWH News - November 10, 2018 Category: Hospital Management Source Type: news

Hospital-diagnosed atopic dermatitis and long-term risk of myocardial infarction: a population-based follow-up study
Conclusions Hospital-diagnosed AD was associated with increased risk of MI compared with the general population.
Source: BMJ Open - November 10, 2016 Category: Journals (General) Authors: Riis, J. L., Vestergaard, C., Hjuler, K. F., Iversen, L., Jakobsen, L., Deleuran, M. S., Olsen, M. Tags: Open access, Cardiovascular medicine, Dermatology Research Source Type: research

Risk of Myocardial Infarction and Stroke in Patients With Granulomatosis With Polyangiitis (Wegener's): A Population ‐Based Study
ConclusionPatients with GPA have a significantly increased risk of MI and a non–statistically significant trend toward an increased risk of ischemic stroke. Monitoring for this complication and vigilance in modifying risk factors are particularly warranted in this patient population, especially early after the diagnosis of GPA.
Source: Arthritis and Rheumatism - September 28, 2016 Category: Rheumatology Authors: J. Antonio Avi ña‐Zubieta, Alice Mai, Neda Amiri, Natasha Dehghan, Ju Ann Tan, Eric C. Sayre, Hyon K. Choi Tags: Full Length Source Type: research

Risk of Myocardial Infarction and Stroke in Patients with Granulomatosis with Polyangiitis: A Population‐Based Study
Conclusion: GPA patients have a significantly increased risk of MI, with a non‐statistically significant trend towards increased risk of ischemic stroke. Monitoring for this complication and vigilance in modifying risk factors is particularly warranted in this patient population, especially early after diagnosis. This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatism - May 22, 2016 Category: Rheumatology Authors: J. Antonio Aviña‐Zubieta, Alice Mai, Neda Amiri, Natasha Dehghan, Ju Ann Tan, Eric C. Sayre, Hyon K. Choi Tags: Full Length Source Type: research

Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?
Authors: Ridker PM Abstract Inflammation contributes to all phases of the atherothrombotic process, patients with elevated inflammatory biomarkers such as high-sensitivity C-reactive protein (hsCRP) have increased cardiovascular risk, and recent work directly implicates the interleukin-1 (IL-1) and interleukin-6 (IL-6) pathways in atherogenesis. Yet, it remains unknown whether targeted inhibition of inflammation will reduce cardiovascular event rates. To address directly this fundamental hypothesis, our research group has initiated two large-scale, randomized, placebo-controlled trials using targeted anti-inflammat...
Source: Transactions of the American Clinical and Climatological Association - June 4, 2015 Category: Journals (General) Tags: Trans Am Clin Climatol Assoc Source Type: research

Hacking The Nervous System
(Photo: © Job Boot) One nerve connects your vital organs, sensing and shaping your health. If we learn to control it, the future of medicine will be electric.When Maria Vrind, a former gymnast from Volendam in the Netherlands, found that the only way she could put her socks on in the morning was to lie on her back with her feet in the air, she had to accept that things had reached a crisis point. “I had become so stiff I couldn’t stand up,” she says. “It was a great shock because I’m such an active person.”It was 1993. Vrind was in her late 40s and working two jobs, athletics coach and a carer for disabled ...
Source: Science - The Huffington Post - May 30, 2015 Category: Science Source Type: news